Compare Meta Platforms Inc (META) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs Sana Biotechnology Inc — how do they compare? Meta Platforms Inc trades at $718.67 (market cap $1.84T), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Meta Platforms Inc is far larger — about 2199.1× Sana Biotechnology Inc's market cap, and Meta Platforms Inc pays a 0.29% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and Sana Biotechnology Inc for 23 Days on average.
| META | SANA | |
|---|---|---|
Market Cap | $1.84T | $836.71M |
Volume | 15,887,049 | 4,507,444 |
Sector | Media | Health |
52-Week High | $777.59 | $5.92 |
52-Week Low | $525.72 | $2.68 |
Typical Hold Time | 127 Days | 23 Days |
Enterprise Value | $1.86T | $749.96M |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $720.89, down 0.06% on the day, with a bullish technical signal from moving averages and key support at $714. Revenue grew to $201.0B in 2025, though net income dipped to $60.5B, and the company launched its powerful Muse Spark AI model, driving positive sentiment. Valuation ratios include a P/E of 27.15 and P/S of 8.11, reflecting premium pricing amid strong profitability with an 81.75% gross margin.
The outlook is positive, with analyst consensus at Buy (80%) and a $781 price target, supported by AI innovation and earnings beats, but risks include a recent EPS miss, regulatory lawsuits, and high capital expenditures. Investors should weigh growth potential against legal and competitive pressures in the social media sector.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
